Masthead

Accelerate your Oncology Research

Masthead

The aggressive pace of oncology research is characterized by large-scale, multidisciplinary efforts such as The Cancer Genome Atlas, The Human Protein Atlas, and Precision Medicine Initiative. With a broader and deeper understanding of the biology and signaling pathways that lead to cancer, scientists are better equipped to identify, characterize, and target biomarkers that can be translated into clinical applications. However, with these recent advancements comes a desperate need to understand the influence of the tumor microenvironment on cancer progression, evolution, and the resulting immune response. To make this next leap forward, scientists need tools that enable them to take an integrated, multi-omic, and 360° view of the tumor, immune response and microenvironment.

Challenges

Novel single-cell cancer genomics studies and spatial biology have led to new insights on tumor heterogeneity. NanoString’s GeoMx Digital Spatial Profiling (DSP) technology allows for a thorough exploration of the complex interactions with the tumor microenvironment through visualization and quantification of transcripts and proteins on individual tissue sections

Coupled with nCounter expression panels focused on clinical research, immuno-oncology, cancer metabolism, and CAR-T cell therapy, NanoString provides solutions for every step of the way in cancer research, from bulk gene expression analysis to spatial profiling.

NanoString offers solutions that overcome the biggest challenges in cancer research:

  • The complex interactions between the tumor and microenvironment
  • A highly heterogeneous disease that leads to variable therapeutic response
  • An ever-increasing number of possible therapeutic targets and combination trials

NanoString’s nCounter oncology gene expression panel portfolio has driven innovation since its inception, starting with the initial Hallmarks of Cancer Panel Collection and the best-selling PanCancer Immune Profiling Panel and PanCancer Pathways Panel. Expanding on this, the 360 Series Panel Collection and Data Analysis Service allow researchers to better understand therapeutic response/mechanism of action, immune evasion, and the interplay between the tumor and microenvironment.

Case Studies

Biomarkers for adjuvant
therapy predict benefit in early stage triple negative breast cancer

Read More
3d model of a cell

PanCancer IO 360
& GeoMx DSP Case Study – Pediatric Primary and Metastatic Osteosarcoma

Read More
Case Study

Related Resources

View All Resources
Blog From an Egyptian Papyrus to the Hallmarks of Cancer: A Journey through the Development of Knowledge in Oncology Research
Blog Going Beyond PDL-1. Q&A with Dr. Nina Radosevic- Robin, MD.
Blog Q&A with Dr. Lisa Butterfield, PhD: Cancer Vaccines & Adoptive Cell Transfer
Blog How the Field of Immuno-Oncology is Changing Fast
Tradeshow/Conference Advancing Science: A Virtual Oncology Conference

Publications

View All Publications

A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.

Small B-cell lymphoid neoplasms (SBCLNs) are a heterogeneous group of diseases characterized by malignant clonal proliferation of mature B-cells. However, the classification of SBCLNs remains a challenge, especially in cases where histopathological analysis is unavailable or those with atypical laboratory findings or equivocal pathologic data.

Remodeling of the tumor microenvironment via disrupting Blimp1(+) effector Treg activity augments response to anti-PD-1 blockade.

BACKGROUND: Accumulation of Foxp3(+) regulatory T (Treg) cells in the tumor often represents an important mechanism for cancer immune evasion and a critical barrier to anti-tumor immunity and immunotherapy. Many tumor-infiltrating Treg cells display an activated phenotype and express the transcription factor Blimp1.

Expression of CIB1 correlates with colorectal liver metastases but not with peritoneal carcinomatosis.

Background: Molecular differences in colorectal cancer (CRC) are associated with the metastatic route. Patient survival is mainly driven by metastatic spread thus it is imperative to understand its key drivers to develop biomarkers for risk stratification, follow-up protocols and personalized therapy.